Filipe A. Moura, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetes Mellitus, Type 2 | 9 | 2024 | 12252 | 0.640 |
Why?
|
Myocardial Infarction | 8 | 2023 | 11519 | 0.580 |
Why?
|
Dyslipidemias | 3 | 2019 | 873 | 0.490 |
Why?
|
Insulin Resistance | 4 | 2019 | 3986 | 0.460 |
Why?
|
Insulin | 5 | 2019 | 6607 | 0.450 |
Why?
|
Endothelium, Vascular | 4 | 2021 | 4427 | 0.450 |
Why?
|
Weight Loss | 2 | 2024 | 2721 | 0.430 |
Why?
|
Periodicity | 1 | 2013 | 348 | 0.390 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2023 | 2298 | 0.320 |
Why?
|
Cardiovascular Diseases | 6 | 2024 | 15662 | 0.300 |
Why?
|
Seasons | 1 | 2013 | 1524 | 0.280 |
Why?
|
Blood Glucose | 4 | 2021 | 6430 | 0.280 |
Why?
|
Benzhydryl Compounds | 3 | 2023 | 944 | 0.280 |
Why?
|
Cholesterol, HDL | 4 | 2019 | 1820 | 0.270 |
Why?
|
Diabetes Mellitus | 2 | 2022 | 5889 | 0.250 |
Why?
|
Gastric Inhibitory Polypeptide | 2 | 2023 | 69 | 0.250 |
Why?
|
Sodium-Glucose Transporter 2 | 1 | 2023 | 89 | 0.210 |
Why?
|
Niacin | 1 | 2014 | 117 | 0.210 |
Why?
|
Triglycerides | 3 | 2024 | 2464 | 0.210 |
Why?
|
Vasodilation | 3 | 2021 | 967 | 0.200 |
Why?
|
Apolipoprotein C-III | 1 | 2024 | 210 | 0.200 |
Why?
|
Lipoproteins, HDL | 2 | 2019 | 682 | 0.190 |
Why?
|
Brazil | 5 | 2021 | 1250 | 0.190 |
Why?
|
Oligonucleotides | 1 | 2024 | 563 | 0.180 |
Why?
|
Hypertriglyceridemia | 1 | 2024 | 293 | 0.180 |
Why?
|
Plaque, Atherosclerotic | 1 | 2012 | 1551 | 0.180 |
Why?
|
Catheters | 1 | 2024 | 427 | 0.180 |
Why?
|
Anti-Obesity Agents | 1 | 2024 | 240 | 0.180 |
Why?
|
Glyburide | 1 | 2021 | 117 | 0.180 |
Why?
|
Glucosides | 2 | 2022 | 533 | 0.170 |
Why?
|
Sarcopenia | 2 | 2017 | 378 | 0.170 |
Why?
|
Hypoglycemic Agents | 3 | 2023 | 3109 | 0.170 |
Why?
|
Atherosclerosis | 2 | 2012 | 3433 | 0.170 |
Why?
|
Vasodilator Agents | 1 | 2014 | 990 | 0.170 |
Why?
|
Weight Gain | 2 | 2019 | 2359 | 0.150 |
Why?
|
Fatty Acids, Omega-3 | 2 | 2019 | 1399 | 0.140 |
Why?
|
Carotid Artery Diseases | 2 | 2021 | 879 | 0.140 |
Why?
|
Simvastatin | 1 | 2019 | 346 | 0.140 |
Why?
|
Overweight | 2 | 2019 | 2448 | 0.140 |
Why?
|
Coronary Artery Disease | 4 | 2024 | 6568 | 0.140 |
Why?
|
Disease Progression | 2 | 2024 | 13671 | 0.130 |
Why?
|
Glucose Clamp Technique | 2 | 2013 | 263 | 0.130 |
Why?
|
Heart Valve Diseases | 1 | 2024 | 1030 | 0.130 |
Why?
|
Risk Factors | 12 | 2024 | 74944 | 0.130 |
Why?
|
No-Reflow Phenomenon | 1 | 2015 | 16 | 0.130 |
Why?
|
Indoles | 1 | 2014 | 1836 | 0.130 |
Why?
|
Risk Assessment | 5 | 2024 | 24315 | 0.130 |
Why?
|
Aged | 16 | 2024 | 171504 | 0.120 |
Why?
|
Hydroxycholesterols | 1 | 2014 | 23 | 0.120 |
Why?
|
Glomerular Filtration Rate | 1 | 2023 | 2227 | 0.120 |
Why?
|
Middle Aged | 19 | 2024 | 223492 | 0.120 |
Why?
|
Brachial Artery | 1 | 2015 | 373 | 0.110 |
Why?
|
Environment Design | 1 | 2015 | 174 | 0.110 |
Why?
|
Treatment Outcome | 7 | 2024 | 65371 | 0.100 |
Why?
|
Inflammation | 3 | 2019 | 10873 | 0.100 |
Why?
|
Cooking | 1 | 2015 | 327 | 0.100 |
Why?
|
Humans | 31 | 2024 | 768166 | 0.100 |
Why?
|
Frail Elderly | 2 | 2019 | 781 | 0.100 |
Why?
|
Seafood | 1 | 2015 | 395 | 0.090 |
Why?
|
Ventricular Remodeling | 1 | 2019 | 1281 | 0.090 |
Why?
|
Age Factors | 5 | 2017 | 18412 | 0.090 |
Why?
|
Nonlinear Dynamics | 1 | 2013 | 493 | 0.090 |
Why?
|
Male | 19 | 2024 | 364719 | 0.090 |
Why?
|
Female | 19 | 2024 | 397192 | 0.080 |
Why?
|
Cholesterol, LDL | 2 | 2024 | 2403 | 0.080 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2020 | 2145 | 0.080 |
Why?
|
Arteries | 1 | 2014 | 1127 | 0.080 |
Why?
|
Coronary Angiography | 3 | 2017 | 4541 | 0.080 |
Why?
|
Sirtuins | 1 | 2012 | 322 | 0.080 |
Why?
|
Hypolipidemic Agents | 2 | 2024 | 609 | 0.080 |
Why?
|
Prospective Studies | 7 | 2021 | 54926 | 0.080 |
Why?
|
Accidents, Traffic | 1 | 2015 | 818 | 0.080 |
Why?
|
Energy Intake | 1 | 2017 | 2146 | 0.080 |
Why?
|
Body Mass Index | 2 | 2024 | 13053 | 0.080 |
Why?
|
Peripheral Arterial Disease | 2 | 2024 | 1304 | 0.080 |
Why?
|
Sex Distribution | 1 | 2013 | 2278 | 0.070 |
Why?
|
Kidney | 1 | 2023 | 7064 | 0.070 |
Why?
|
Patient Admission | 1 | 2015 | 1365 | 0.070 |
Why?
|
ROC Curve | 1 | 2015 | 3628 | 0.070 |
Why?
|
Age Distribution | 1 | 2013 | 2873 | 0.070 |
Why?
|
Fasting | 1 | 2013 | 1610 | 0.070 |
Why?
|
Body Composition | 1 | 2017 | 2462 | 0.070 |
Why?
|
Follow-Up Studies | 3 | 2019 | 39348 | 0.070 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2019 | 3251 | 0.070 |
Why?
|
C-Reactive Protein | 2 | 2015 | 3858 | 0.070 |
Why?
|
Nitric Oxide | 1 | 2015 | 2146 | 0.070 |
Why?
|
Obesity | 2 | 2024 | 13090 | 0.060 |
Why?
|
Aged, 80 and over | 6 | 2019 | 59629 | 0.060 |
Why?
|
Genome-Wide Association Study | 1 | 2024 | 12795 | 0.060 |
Why?
|
Stress, Physiological | 1 | 2011 | 1408 | 0.060 |
Why?
|
Lipids | 1 | 2015 | 3343 | 0.050 |
Why?
|
Aging | 2 | 2012 | 8744 | 0.050 |
Why?
|
Enteroendocrine Cells | 1 | 2024 | 79 | 0.050 |
Why?
|
Isoprostanes | 1 | 2022 | 21 | 0.050 |
Why?
|
Hyperglycemia | 1 | 2011 | 1388 | 0.050 |
Why?
|
Apolipoproteins B | 1 | 2024 | 386 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3115 | 0.050 |
Why?
|
Sex Factors | 2 | 2013 | 10632 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3238 | 0.050 |
Why?
|
Wounds and Injuries | 1 | 2015 | 2517 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 1 | 2024 | 18065 | 0.050 |
Why?
|
Muscle, Skeletal | 1 | 2017 | 4978 | 0.050 |
Why?
|
Oligonucleotides, Antisense | 1 | 2024 | 462 | 0.050 |
Why?
|
Receptor, Angiotensin, Type 2 | 1 | 2020 | 61 | 0.040 |
Why?
|
Delayed-Action Preparations | 1 | 2014 | 969 | 0.040 |
Why?
|
Sensitivity and Specificity | 1 | 2015 | 14729 | 0.040 |
Why?
|
Logistic Models | 4 | 2017 | 13290 | 0.040 |
Why?
|
Double-Blind Method | 2 | 2024 | 12465 | 0.040 |
Why?
|
Cross-Sectional Studies | 3 | 2019 | 26379 | 0.040 |
Why?
|
Echocardiography | 2 | 2024 | 5047 | 0.040 |
Why?
|
Ventricular Function, Left | 2 | 2023 | 3941 | 0.040 |
Why?
|
Heart Failure | 1 | 2023 | 11879 | 0.040 |
Why?
|
Endothelial Cells | 2 | 2024 | 3589 | 0.040 |
Why?
|
Chloroquine | 1 | 2020 | 276 | 0.040 |
Why?
|
Time Factors | 3 | 2021 | 40218 | 0.040 |
Why?
|
Adenosine Monophosphate | 1 | 2020 | 232 | 0.040 |
Why?
|
Takotsubo Cardiomyopathy | 1 | 2020 | 125 | 0.040 |
Why?
|
Cohort Studies | 2 | 2019 | 41754 | 0.040 |
Why?
|
Epigenomics | 1 | 2024 | 960 | 0.040 |
Why?
|
Stroke Volume | 2 | 2023 | 5622 | 0.040 |
Why?
|
Cholesterol | 2 | 2019 | 2914 | 0.040 |
Why?
|
Cross-Over Studies | 1 | 2014 | 2107 | 0.040 |
Why?
|
Islets of Langerhans | 1 | 2024 | 1351 | 0.040 |
Why?
|
Alanine | 1 | 2020 | 614 | 0.040 |
Why?
|
Diet | 1 | 2015 | 8089 | 0.040 |
Why?
|
Sphingosine | 1 | 2019 | 308 | 0.030 |
Why?
|
Adipocytes | 1 | 2024 | 1197 | 0.030 |
Why?
|
Young Adult | 4 | 2019 | 60066 | 0.030 |
Why?
|
Lysophospholipids | 1 | 2019 | 338 | 0.030 |
Why?
|
Diabetic Nephropathies | 1 | 2024 | 973 | 0.030 |
Why?
|
Plasma | 1 | 2020 | 585 | 0.030 |
Why?
|
Platelet Aggregation | 1 | 2019 | 769 | 0.030 |
Why?
|
Virus Internalization | 1 | 2020 | 504 | 0.030 |
Why?
|
Prevalence | 1 | 2013 | 15869 | 0.030 |
Why?
|
Hydroxychloroquine | 1 | 2020 | 426 | 0.030 |
Why?
|
Multifactorial Inheritance | 1 | 2024 | 1422 | 0.030 |
Why?
|
Portugal | 1 | 2015 | 91 | 0.030 |
Why?
|
Butter | 1 | 2015 | 22 | 0.030 |
Why?
|
Homeostasis | 2 | 2019 | 3348 | 0.030 |
Why?
|
Adult | 6 | 2024 | 223646 | 0.030 |
Why?
|
Soybean Oil | 1 | 2015 | 139 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 3 | 2019 | 36743 | 0.030 |
Why?
|
Odds Ratio | 2 | 2017 | 9669 | 0.030 |
Why?
|
Asymptomatic Diseases | 1 | 2017 | 590 | 0.030 |
Why?
|
Echocardiography, Three-Dimensional | 1 | 2019 | 615 | 0.030 |
Why?
|
Nutrition Assessment | 1 | 2017 | 740 | 0.030 |
Why?
|
Fatty Acids, Omega-6 | 1 | 2015 | 225 | 0.030 |
Why?
|
Antimalarials | 1 | 2020 | 909 | 0.030 |
Why?
|
Metformin | 1 | 2021 | 909 | 0.030 |
Why?
|
Infant, Newborn | 1 | 2013 | 26422 | 0.030 |
Why?
|
Population Growth | 1 | 2012 | 50 | 0.030 |
Why?
|
Muscle Strength | 1 | 2017 | 640 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2024 | 2540 | 0.020 |
Why?
|
Chromatin | 1 | 2024 | 2981 | 0.020 |
Why?
|
Neoplasms | 1 | 2020 | 22371 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2019 | 4860 | 0.020 |
Why?
|
Exercise Tolerance | 1 | 2017 | 846 | 0.020 |
Why?
|
Antioxidants | 1 | 2019 | 1673 | 0.020 |
Why?
|
Fishes | 1 | 2015 | 606 | 0.020 |
Why?
|
Infant | 1 | 2013 | 36535 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2017 | 12077 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2021 | 6316 | 0.020 |
Why?
|
Blood Chemical Analysis | 1 | 2012 | 435 | 0.020 |
Why?
|
Absorptiometry, Photon | 1 | 2017 | 1758 | 0.020 |
Why?
|
Species Specificity | 1 | 2015 | 2415 | 0.020 |
Why?
|
Safety | 1 | 2015 | 1159 | 0.020 |
Why?
|
Child, Preschool | 1 | 2013 | 42669 | 0.020 |
Why?
|
C-Peptide | 1 | 2011 | 443 | 0.020 |
Why?
|
Geriatric Assessment | 1 | 2017 | 1422 | 0.020 |
Why?
|
Exercise Test | 1 | 2017 | 2186 | 0.020 |
Why?
|
Adolescent | 2 | 2015 | 89169 | 0.020 |
Why?
|
Nutritional Status | 1 | 2017 | 1628 | 0.020 |
Why?
|
Oxidative Stress | 1 | 2019 | 3139 | 0.020 |
Why?
|
Animals | 3 | 2019 | 169246 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2020 | 3073 | 0.020 |
Why?
|
Glucose | 1 | 2019 | 4352 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2023 | 15454 | 0.020 |
Why?
|
Heart Ventricles | 1 | 2019 | 3841 | 0.020 |
Why?
|
Fatty Acids | 1 | 2015 | 1812 | 0.020 |
Why?
|
Adiposity | 1 | 2017 | 1895 | 0.020 |
Why?
|
Hospitalization | 2 | 2019 | 10840 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2023 | 10399 | 0.020 |
Why?
|
Child | 1 | 2013 | 80917 | 0.010 |
Why?
|
Severity of Illness Index | 2 | 2012 | 15948 | 0.010 |
Why?
|
Insulin-Secreting Cells | 1 | 2011 | 899 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2011 | 6229 | 0.010 |
Why?
|
Up-Regulation | 1 | 2011 | 4146 | 0.010 |
Why?
|
Acute Disease | 1 | 2012 | 7243 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8748 | 0.010 |
Why?
|
Comorbidity | 1 | 2012 | 10590 | 0.010 |
Why?
|
Signal Transduction | 1 | 2019 | 23645 | 0.010 |
Why?
|
Incidence | 1 | 2012 | 21538 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2015 | 20760 | 0.010 |
Why?
|
Prognosis | 1 | 2012 | 30010 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2015 | 81762 | 0.000 |
Why?
|